B-cell Lymphoma Clinical Trials in Nashville, Tennessee

4 studies are recruiting for b-cell lymphoma in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

    The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Tennessee Oncology Nashville St Thomas Midtown Clinic, Nashville, Tennessee
    Locations
    155 in total
    Run by
    BeOne Medicines

    See if you can join NCT06742996 on ClinicalTrials.gov

  2. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    51 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07101328 on ClinicalTrials.gov

  3. Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

    The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi)…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    6 in total
    Run by
    Nurix Therapeutics, Inc.

    See if you can join NCT07516093 on ClinicalTrials.gov

  4. Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

    The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    6 in total
    Run by
    Nurix Therapeutics, Inc.

    See if you can join NCT07520006 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.